Insights into the role of chemotherapy and thyroid peroxidase antibodies in risk for primary hypothyroidism among childhood cancer survivors
Abstract
A new study has found that chemotherapy does not increase risk for primary hypothyroidism, but that cisplatin increases this risk in combination with radiation therapy in childhood cancer survivors. This and other findings, including the prevalence of thyroid peroxidase antibodies among survivors, are discussed in the context of previous studies and suggestions for future research.Keywords
This publication has 10 references indexed in Scilit:
- Immune checkpoint inhibitor-induced thyroiditis and its potential mechanismsFrontiers in Endocrinology, 2025
- Incidence and risk factors associated with the development of hypothyroidism after postoperative chemoradiotherapy for head and neck cancer patients with high-risk features: Supplementary analysis of JCOG1008Oral Oncology, 2024
- Checkpoint Immunotherapy in Pediatric Oncology: Will We Say Checkmate Soon?Vaccines, 2023
- Primary hypothyroidism in childhood cancer survivors: Prevalence, risk factors, and long‐term consequencesCancer, 2021
- Population-based estimates of humoral autoimmunity from the U.S. National Health and Nutrition Examination Surveys, 1960–2014PLOS ONE, 2020
- Hypothyroidism after Radiation Therapy for Childhood Cancer: A Report from the Childhood Cancer Survivor StudyRadiation Research, 2018
- The Prevalence, Incidence and Natural Course of Positive Antithyroperoxidase Antibodies in a Population-Based Study: Tehran Thyroid StudyPLOS ONE, 2017
- Endocrine Abnormalities in Aging Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor StudyJournal of Clinical Oncology, 2016
- Risk factors for radiation‐induced hypothyroidismCancer, 2011
- Hypothyroidism following childhood cancer therapy–an under diagnosed complicationInternational Journal of Cancer, 2011